Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study

Sarah Parish, Jemma C Hopewell, Michael R Hill, Santica Marcovina, Elsa Valdes-Marquez, Richard Haynes, Alison Offer, Terje R Pedersen, Colin Baigent, Rory Collins, Martin Landray, Jane Armitage, HPS2-THRIVE Collaborative Group, Sarah Parish, Jemma C Hopewell, Michael R Hill, Santica Marcovina, Elsa Valdes-Marquez, Richard Haynes, Alison Offer, Terje R Pedersen, Colin Baigent, Rory Collins, Martin Landray, Jane Armitage, HPS2-THRIVE Collaborative Group

Abstract

Background: Genetic studies have shown lipoprotein(a) (Lp[a]) to be an important causal risk factor for coronary disease. Apolipoprotein(a) isoform size is the chief determinant of Lp(a) levels, but its impact on the benefits of therapies that lower Lp(a) remains unclear.

Methods: HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) is a randomized trial of niacin-laropiprant versus placebo on a background of simvastatin therapy. Plasma Lp(a) levels at baseline and 1 year post-randomization were measured in 3978 participants from the United Kingdom and China. Apolipoprotein(a) isoform size, estimated by the number of kringle IV domains, was measured by agarose gel electrophoresis and the predominantly expressed isoform identified.

Results: Allocation to niacin-laropiprant reduced mean Lp(a) by 12 (SE, 1) nmol/L overall and 34 (6) nmol/L in the top quintile by baseline Lp(a) level (Lp[a] ≥128 nmol/L). The mean proportional reduction in Lp(a) with niacin-laropiprant was 31% but varied strongly with predominant apolipoprotein(a) isoform size (PTrend=4×10-29) and was only 18% in the quintile with the highest baseline Lp(a) level and low isoform size. Estimates from genetic studies suggest that these Lp(a) reductions during the short term of the trial might yield proportional reductions in coronary risk of ≈2% overall and 6% in the top quintile by Lp(a) levels.

Conclusions: Proportional reductions in Lp(a) were dependent on apolipoprotein(a) isoform size. Taking this into account, the likely benefits of niacin-laropiprant on coronary risk through Lp(a) lowering are small. Novel therapies that reduce high Lp(a) levels by at least 80 nmol/L (≈40%) may be needed to produce worthwhile benefits in people at the highest risk because of Lp(a).

Clinical trial registration: URL: https://ichgcp.net/clinical-trials-registry/NCT00461630" title="See in ClinicalTrials.gov">NCT00461630.

Keywords: apolipoprotein(a); clinical trial; coronary disease; isoform size; lipoprotein(a); therapeutics.

© 2018 The Authors.

Figures

Figure 1.
Figure 1.
Baseline lipoprotein(a) (Lp[a]) levels by the kringle IV domains of the predominantly expressed apolipoprotein(a) isoform, within the United Kingdom and China. Blue circles denote United Kingdom, and red squares denote China. The 11 kringle IV domain groups shown are ≤15, 16, 17, 18, 19, 20 to 21, 22 to 23, 24 to 25, 26 to 27, 28 to 30, and ≥31. Lp(a) indicates lipoprotein(a).
Figure 2.
Figure 2.
Percentage and absolute reductions in lipoprotein(a) (Lp[a]) with niacin–laropiprant by quintiles of baseline Lp(a) levels and kringle IV domains. Percentage reduction panels show adjusted Lp(a) reductions based on modeling loge Lp(a) (Methods) and are plotted with an x scale linear in the loge Lp(a) difference. Absolute reductions (with adjustment by stratification) are plotted on linear scales. Usual mean Lp(a) is the mean Lp(a) in the placebo arm at 1 y.

References

    1. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853. doi: 10.1093/eurheartj/ehq386.
    1. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–1975. doi: 10.1194/jlr.R071233.
    1. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528. doi: 10.1056/NEJMoa0902604.
    1. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 2011;7:e1002260.
    1. Ronald J, Rajagopalan R, Cerrato F, Nord AS, Hatsukami T, Kohler T, et al. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke. 2011;42:2–9. doi: 10.1161/STROKEAHA.110.591230.
    1. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol. 2010;4:240–247. doi: 10.1016/j.jacl.2010.07.002.
    1. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851–860. doi: 10.1016/j.jacc.2014.03.061.
    1. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423.
    1. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:1956–1967.
    1. Dati F, Tate JR, Marcovina SM, Steinmetz A International Federation of Clinical Chemistry and Laboratory Medicine; IFCC Working Group for Lipoprotein(a) Assay Standardization. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay–Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42:670–676. doi: 10.1515/CCLM.2004.114.
    1. Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of niacin in the United States and Canada. JAMA Intern Med. 2013;173:1379–1381. doi: 10.1001/jamainternmed.2013.6489.
    1. U.S. National Library of Medicine. ClinicalTrials; gov. Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL). . Accessed October 30, 2017.
    1. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
    1. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
    1. Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, et al. AIM-HIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014;371:288–290. doi: 10.1056/NEJMc1311039.
    1. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415. doi: 10.1056/NEJMoa1009744.
    1. Desai NR, Kohli P, Giugliano RP, O’Donoghue ML, Somaratne R, Zhou J, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013;128:962–969. doi: 10.1161/CIRCULATIONAHA.113.001969.
    1. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. doi: 10.1186/s12916-015-0358-8.
    1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664.
    1. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016;57:1086–1096. doi: 10.1194/jlr.P065334.
    1. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291.
    1. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246–255.
    1. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436–439.
    1. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
    1. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–2639. doi: 10.1016/j.jacc.2012.09.017.
    1. Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, et al. Heart Protection Study Collaborative Group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011;4:68–73. doi: 10.1161/CIRCGENETICS.110.958371.
    1. Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. CHARGE–Heart Failure Consortium; CARDIoGRAM Exome Consortium. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68:2761–2772. doi: 10.1016/j.jacc.2016.10.033.
    1. van Capelleveen JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). J Lipid Res. 2016;57:1612–1618. doi: 10.1194/jlr.R053066.
    1. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483. doi: 10.1016/S0140-6736(15)61252-1.
    1. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW., III Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360.e2. doi: 10.1016/j.ahj.2008.09.022.
    1. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23:560–568. doi: 10.1097/MOL.0b013e3283598d81.
    1. Bonen DK, Nassir F, Hausman AM, Davidson NO. Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro. J Lipid Res. 1998;39:1629–1640.
    1. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273:6–30. doi: 10.1111/j.1365-2796.2012.02592.x.
    1. Kostner KM, Clodi M, Bodlaj G, Watschinger B, Hörl W, Derfler K, et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest. 1998;28:447–452.
    1. Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:2686–2693. doi: 10.1161/ATVBAHA.115.306136.
    1. Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53:2405–2412. doi: 10.1194/jlr.M029769.
    1. Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2017;37:1770–1775. doi: 10.1161/ATVBAHA.117.309549.
    1. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649–11662. doi: 10.1074/jbc.M114.611988.
    1. Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352–362. doi: 10.1161/CIRCULATIONAHA.116.025253.
    1. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler Thromb Vasc Biol. 2017;37:580–588. doi: 10.1161/ATVBAHA.116.308704.
    1. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014;130:431–441. doi: 10.1161/CIRCULATIONAHA.113.006720.
    1. Albers JJ, Koschinsky ML, Marcovina SM. Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 2007;71:961–962. doi: 10.1038/sj.ki.5002240.
    1. Mack S, Coassin S, Rueedi R, Yousri NA, Seppälä I, Gieger C, et al. KORA-Study Group. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J Lipid Res. 2017;58:1834–1844. doi: 10.1194/jlr.M076232.
    1. Yanez ND, III, Kronmal RA, Shemanski LR. The effects of measurement error in response variables and tests of association of explanatory variables in change models. Stat Med. 1998;17:2597–2606.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться